There are unmet medical and social needs for a well priced, FDA-approved ophthalmic formulation of bevacizumab to treat retinal diseases.
Outlook Therapeutics is working to meet these needs. If approved and commercialized for ophthalmic use, ONS-5010 has the potential to help address the existing quality, safety and availability issues associated with unapproved repackaged IV bevacizumab from compounding pharmacies (e.g., cGMP-quality control issues, product shortages, inconsistent potency, sterility issues, syringe malfunctions, and liability risks associated with use of unapproved repackaged IV bevacizumab).
Additionally, if ONS-5010 is approved and commercialized, the Company expects to price it responsibly to help mitigate the high cost of on-label treatment for retinal diseases. Both in the United States and globally, the high cost of treating retinal diseases such as wet AMD, DME and BRVO can result in patients receiving an insufficient number of treatments, or potentially no treatment at all.
ONS-5010 has the potential, if approved and commercialized with a responsible pricing strategy, to help lower the aggregate costs of treating retinal diseases for the overall healthcare system.